CHADS2 Best Predictor of Postoperative Mortality Risk

This article originally appeared here.
Share this content:
CHADS<sub>2</sub> Best Predictor of Postoperative Mortality Risk
CHADS2 Best Predictor of Postoperative Mortality Risk

FRIDAY, Sept. 4, 2015 (HealthDay News) -- The CHADS2 atrial fibrillation (AF) risk score is the best predictor of postoperative stroke or death regardless of type of surgery, according to a study published online Aug. 13 in the Journal of Thrombosis and Haemostasis.

Finlay A. McAlister, M.D., from the University of Alberta in Edmonton, Canada, and colleagues assessed the accuracy of AF thromboembolic risk models (the CHADS2, CHA2DS2-VASc, and R2CHADS2 scores) versus the Revised Cardiac Risk Index (RCRI) among an international cohort of patients (≥45 years of age) undergoing inpatient, non-cardiac surgery with 30 days of post-surgery follow-up.

The researchers found that the 961 patients with preoperative AF were at higher risk for any cardiovascular event in the postoperative period compared with the 13,001 patients without AF (26.6 versus 9 percent, respectively; adjusted odds ratio, 1.58). All thromboembolic risk scores predicted postoperative death as well as the RCRI. The CHADS2 significantly improved postoperative stroke/mortality risk prediction compared to the RCRI, largely because of improved discrimination of patients who did not subsequently have an event.

"In AF patients, the three thromboembolic risk scores performed similarly to the RCRI in predicting death within 30 days and the CHADS2 score was the best predictor of postoperative stroke/death regardless of type of surgery," the authors write.

One author disclosed financial ties to medical device and pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »